Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3]. - The lawsuit alleges that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the regulatory prospects of its INO-3107 Biologics License Application [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action settlements [4].

Core Viewpoint - The weight loss drug market is emerging as a significant growth opportunity in the pharmaceutical industry, comparable to the technology sector, with Eli Lilly and Viking Therapeutics as key players [1][2]. Eli Lilly - Eli Lilly leads the weight loss drug market with a 60% share, driven by its products Mounjaro and Zepbound, which have shown triple-digit revenue growth [5][13]. - The company entered the GLP-1 drug market after Novo Nordisk and has focused on increasing manufacturing capacity to meet demand [4][5]. - Lilly's oral weight loss drug is currently under regulatory review, potentially expanding its market presence [6]. Viking Therapeutics - Viking Therapeutics is advancing its candidate VK2735 into phase 3 trials, with promising results suggesting it could compete effectively with Lilly and Novo's offerings [8][9]. - The company has another candidate targeting amylin and calcitonin receptors, which are important for metabolism [10]. - Demand for weight loss drugs is high, providing Viking with an opportunity to capture market share if its trials are successful [10]. Investment Considerations - Both Eli Lilly and Viking Therapeutics are viewed as strong investment opportunities in the weight loss drug market, with Lilly currently generating significant revenue and Viking showing potential for future growth [13][15]. - Lilly's stock has seen a decline of about 8% this year, trading at 28 times forward earnings estimates, while Viking's stock has increased by approximately 2% this year [13][14]. - The upcoming regulatory decision on Lilly's oral weight loss drug could serve as a catalyst for its stock price [15].

Core Insights - The company is a fully vertically integrated radiopharma firm specializing in oncology, with a focus on urologic oncology and neuro-oncology [1] - In the past year, the company achieved over $800 million in sales, primarily driven by its U.S. prostate cancer imaging franchise [1] - The company has two FDA-approved products in the prostate cancer imaging space and is actively engaged in therapy trials [1] Commercial Performance - The company has recently issued guidance for its future commercial performance [2]

Core Viewpoint - A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its drug DCCR (VYKAT™ XR) [1][4]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 [1][3]. - The lawsuit was triggered by a disappointing report on November 5, 2025, regarding DCCR, which led to a 26% drop in the company's share price [2][4]. Group 2: Allegations Against Soleno - The litigation focuses on Soleno's statements about DCCR's safety, efficacy, and commercial prospects, which were claimed to be misrepresented [4]. - The lawsuit alleges that Soleno downplayed significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [4]. - It is claimed that DCCR had materially lower commercial viability than disclosed, with undisclosed risks of significant adverse events post-launch [4]. Group 3: Market Reaction and Investor Sentiment - The market reaction began on August 15, 2025, when Scorpion Capital raised concerns about Soleno's disclosures, leading to a nearly 40% decline in share price by November 5, 2025 [5]. - Scorpion Capital highlighted reports of children hospitalized for potential heart failure after using VYKAT™ XR, raising doubts about the drug's market viability [5]. - Soleno's management acknowledged a disruption in their launch trajectory during the Q3 2025 earnings call, attributing it to the negative impact of the short seller report [5].

Core Viewpoint - Corcept Therapeutics is facing a securities class action lawsuit due to alleged misleading statements regarding its lead drug candidate, relacorilant, which has resulted in significant investor losses [2][4][7]. Group 1: Lawsuit Details - The lawsuit, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., was filed in the U.S. District Court for the Northern District of California [2]. - The action seeks to recover losses for all individuals and entities that purchased Corcept common stock between October 31, 2024, and December 30, 2025 [2]. - Investors have until April 21, 2026, to apply for Lead Plaintiff status in the lawsuit [1][4]. Group 2: Allegations Summary - The complaint alleges that Corcept made materially false and misleading statements about relacorilant by failing to disclose critical information regarding its clinical data and FDA communications [4][7]. - The FDA reportedly warned Corcept multiple times in 2024 and early 2025 that its clinical data was insufficient to support a New Drug Application [7]. - Despite knowing the FDA's concerns, Corcept continued to promote Phase 3 results, which were later deemed fundamentally flawed by the FDA [7]. Group 3: Market Impact - On December 31, 2025, Corcept disclosed it received a Complete Response Letter (CRL) from the FDA, indicating an unfavorable benefit-risk assessment for relacorilant due to insufficient evidence [7]. - Following this announcement, Corcept's stock price fell from $70.20 on December 30, 2025, to $34.80 on December 31, 2025, resulting in a loss of nearly $2.5 billion in market capitalization in one day [7].

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 Accessibility StatementSkip NavigationCAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc.(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new data for zidesamtinib, an investigational ROS1-selective inhibitor, du ...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Aquestive an ...

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud and unlawful business practices related to the company's operations [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Corcept and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 21, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired Corcept securities during the Class Period [2]. Group 2: Stock Performance and Regulatory Issues - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, stating that additional evidence of effectiveness was required [4]. - Following the FDA's announcement, Corcept's stock price dropped by $35.40 per share, or 50.4%, closing at $34.80 per share on the same day [4].

Core Viewpoint - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the AACR Annual Meeting 2026, highlighting the company's ongoing efforts in developing advanced cancer treatments [1] Group 1: Presentation Details - The poster presentation will feature safety and preliminary efficacy results from dose finding cohorts of the [Pb]VMT-α-NET program, specifically targeting advanced SSTR2+ neuroendocrine tumors [2] - The presentation is scheduled for April 20, 2026, from 9:00 am to 12:00 pm [2] Group 2: About [Pb]VMT-α-NET - [Pb]VMT-α-NET is designed to target and deliver lead (Pb) to tumor sites expressing somatostatin receptor type 2 (SSTR2) [3] - The company is conducting a multi-center, open-label, dose-escalation, dose-expansion study for patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies [3] Group 3: Interim Analysis and Safety Findings - An interim analysis reported at the ASCO-GI in January 2026 included safety data from 56 patients, with no dose limiting toxicities or serious treatment-related complications reported [4][5] - Among the 56 patients, 21 (37.5%) experienced Grade 3 or higher treatment-emergent adverse events, with one patient experiencing a transient Grade 4 event [6][7] Group 4: Efficacy Data - Updated efficacy analysis indicated that 19 of 25 patients (76%) were without progression and remained alive, including both patients in Cohort 1 [8] - In Cohort 2, 9 patients (39%) showed a response according to investigator-assessed RECIST v1.1, with 8 (35%) of those responses confirmed [8] Group 5: Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, utilizing proprietary technology to deliver alpha-emitting isotopes specifically to cancer cells [9] - The company is also developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes through a "theranostic" approach [9] - The company's ongoing programs include neuroendocrine tumors, melanoma, and solid tumors, all in Phase 1/2a trials in the U.S. [10]

Core Insights - Tonix Pharmaceuticals Holding Corp. announced presentations on its preclinical immuno-oncology portfolio at the AACR Annual Meeting 2026, scheduled for April 17–22, 2026, in San Diego, California [1] Oral Presentation Details - The oral presentation titled "TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression" will take place on April 21, 2026, from 2:30–4:30 p.m. PT [2] - Presenters include Shuang Li, MD, PhD, and Timothy C. Wang, MD, with Tonix co-authors Seth Lederman, MD, and Bruce L. Daugherty, PhD, MBA [2] Poster Presentation Details - The first poster presentation titled "In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies" is scheduled for April 21, 2026, from 2:00-5:00 p.m. PT [3] - The second poster presentation titled "Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice" will occur on April 22, 2026, from 9:00 a.m.–12:00 p.m. PT [3] - Both presentations will be led by Bruce Daugherty, PhD, MBA [3] About TNX-1700 - TNX-1700 is a fusion protein of TFF2 and albumin, currently in preclinical development for treating gastric and colorectal cancer in combination with PD-1 blockade [4] - The drug is in the pre-Investigational New Drug (IND) stages of development and was in-licensed from Columbia University [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments for high unmet medical needs [5] - The company’s marketed products include TONMYA for fibromyalgia, Zembrace® Symtouch® for acute migraines, and Tosymra® [5] - Tonix is also investigating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and has a pipeline including TNX-2900 for Prader-Willi syndrome and monoclonal antibodies for Lyme disease prophylaxis and kidney transplant rejection [5]